trending Market Intelligence /marketintelligence/en/news-insights/trending/iH43jG4_nds5Cwv9SeNk7Q2 content esgSubNav
In This List

NeuroVive raises 28.2M Swedish kronor in direct issue of shares

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


NeuroVive raises 28.2M Swedish kronor in direct issue of shares

NeuroVive Pharmaceutical AB raised 28.2 million Swedish kronor in gross proceeds from a directed new issuance of 20,897,854 shares.

Each share in the issue was priced at 1.35 Swedish kronor, a 5.1% discount to the closing price of NeuroVive's share listed on the Nasdaq Stockholm on March 6.

Proceeds from the issuance will be used to advance drug development activities.

Stockholm Corporate Finance was the financial adviser and sole book runner for the issue.

As of March 13, US$1 was equivalent to 9.31 Swedish kronor.